ClinicalTrials.gg
CompletedNCT04929483ENLIVENUpdated Jan 6, 2026Results posted

Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)

A Phase 2 interventional study of BIO89-100 and Placebo in NASH - Nonalcoholic Steatohepatitis, sponsored by 89bio, Inc.. Completed at 89 sites in 2 countries. Open to participants aged 21 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-06.

Sponsored by 89bio, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
222
Allocation
Randomized
Ages
21 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Enrollment
63rd of 460
222 · median 56
Started
2021
with 56 others
Phase 2
192 of 547
15 open now
Registered
403rd of 547
by date

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 63rd largest by enrollment of the 460 interventional ones that give a count, is one of 57 that started in 2021, is one of 192 in phase 2, and was the 403rd registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 21 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled study that will evaluate the safety, efficacy, tolerability of BIO89-100 in patients with biopsy-confirmed fibrosis stages F2-F3 NASH.

03

Conditions studied

  • NASH - Nonalcoholic Steatohepatitis

Keywords

  • Liver Diseases
  • Fatty Liver
  • Digestive System Diseases
  • Non-alcoholic Fatty Liver Disease
  • Metabolic diseases
  • MASH MAFLD
  • NASH NAFLD
04

Who can participate

Ages eligible
21 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Age 21 to 75
  • -confirmed NASH with fibrosis stage F2 or F3 per NASH CRN System and NAS ≥4, with a score of at least 1 in each of steatosis, ballooning degeneration, and lobular inflammation.

    • Qualifying biopsy must be either within 6 months of screening visit or obtained during screening period

Key Exclusion Criteria:

  • Have poorly controlled high blood pressure
  • Have type 1 diabetes or poorly controlled type 2 diabetes.
  • History of cirrhosis or evidence of cirrhosis by clinical, imaging, or liver biopsy evaluation
  • Are planning to try to lose weight during the conduct of the study.
  • Have a \<25 kg/m2

Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
222 participants (actual)

Study arms

  • Experimental
    BIO89-100 - 15 mg once weekly (QW)

    Drug: BIO89-100

  • Experimental
    BIO89-100 - 30 mg QW

    Drug: BIO89-100

  • Experimental
    BIO89-100 - 44 mg once every 2 weeks (Q2W)

    Drug: BIO89-100

  • Placebo comparator
    Placebo QW

    Drug: Placebo

  • Placebo comparator
    Placebo Q2W

    Drug: Placebo

  • Experimental
    Placebo QW (Main study)/ BIO89-100 - 30 mg QW (Extension)

    Drug: BIO89-100 · Drug: Placebo

Interventions

  • Subcutaneous injection

    Also known as: Pegozafermin

  • DrugPlacebo

    Subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Main Study: Number of Participants With Histological Resolution of Nonalcoholic Steatohepatitis (NASH) Without Worsening of Fibrosis

    Nonalcoholic fatty liver disease activity score (NAS) was the sum of the scores of steatosis, inflammation, and ballooning. NAS score ranged from 0 to 8, with higher scores indicating worse disease severity. Resolution of NASH was defined as the total absence of ballooning (score=0) and absent or mild inflammation (score=0 to 1). NASH clinical research system (CRN) fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis). Worsening of fibrosis was defined as progression of fibrosis greater than or equal to (≥) 1 stage in NASH CRN fibrosis score.

    Time frame: Week 24

  2. Main Study: Number of Participants Who Achieved Improvement of Fibrosis ≥1 Stage Without Worsening of NASH

    Worsening of NASH was defined as increase in nonalcoholic fatty liver disease activity score (NAS) for ballooning, inflammation, or steatosis. NAS was the sum of the scores of steatosis, inflammation, and ballooning. NAS score ranged from 0 to 8, with higher scores indicating worse disease severity. Fibrosis improvement was defined as ≥1-stage decrease in NASH CRN fibrosis score. NASH CRN fibrosis was staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).

    Time frame: Week 24

Secondary outcomes

  1. Main Study: Number of Participants With at Least a 2-Point Improvement in NAS and no Worsening of Fibrosis

    NAS was the sum of the scores of steatosis, inflammation, and ballooning. NAS score ranged from 0 to 8, with higher scores indicating worse disease severity. Worsening of fibrosis was defined as progression of fibrosis ≥1 stage in NASH CRN fibrosis score. NASH CRN fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).

    Time frame: Week 24

  2. Main Study: Number of Participants With NASH Resolution and Fibrosis Improvement ≥1 Stage

    NAS was the sum of the scores of steatosis, inflammation, and ballooning. NAS score ranged from 0 to 8, with higher scores indicating worse disease severity. Resolution of NASH was defined as the total absence of ballooning (score=0) and absent or mild inflammation (score=0 to 1). Fibrosis improvement was defined as ≥1-stage decrease in NASH CRN fibrosis score. NASH CRN fibrosis was staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).

    Time frame: Week 24

  3. Main Study: Number of Participants With at Least a 2-point Improvement in NAS Score and Are Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF) Responders and Alanine Aminotransferase (ALT) Responders

    A responder was defined as achieving ≥2 point improvement in NAS score and are MRI-PDFF responders and ALT responders at Week 24. NAS was the sum of the scores of steatosis, inflammation, and ballooning. NAS score ranged from 0 to 8, with higher scores indicating worse disease severity. MRI-PDFF responder was defined as ≥30% reduction from baseline in liver fat by MRI-PDFF. ALT responder was defined as ≥17 units/liter (U/L) or ≥30% reduction from baseline in ALT.

    Time frame: Week 24

  4. Main Study: Percent Change From Baseline in Serum Triglycerides

    Time frame: Baseline, Week 24

  5. Main Study: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-c)

    Time frame: Baseline, Week 24

  6. Main Study: Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-c)

    Time frame: Baseline, Week 24

  7. Main Study: Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-c)

    Time frame: Baseline, Week 24

  8. Main Study: Percent Change From Baseline in Adiponectin

    Time frame: Baseline, Week 24

  9. Main Study: Percent Change From Baseline in HbA1c (Glycated Hemoglobin)

    Time frame: Baseline, Week 24

  10. Main Study: Percent Change From Baseline in Alanine Transaminase

    Time frame: Baseline, Week 12 and 24

  11. Main Study: Percent Change From Baseline in Hepatic Fat Fraction By Magnetic Resonance Imaging - (MRI-PDFF)

    Time frame: Baseline, Week 12 and 24

  12. Main Study: Percent Change From Baseline in N-Terminal Type III Collagen Propeptide (Pro-C3)

    Time frame: Baseline, Week 12 and 24

  13. Main Study: Trough Serum Concentration of Pegozafermin

    Serum trough concentration (ng/mL) of pegozafermin taken from pre-dose samples.

    Time frame: Predose at Week 12 and 24

  14. Main and Extension Study: Percent Change From Baseline in Alanine Transaminase

    Baseline was prior to dosing on Day 1 of the main study.

    Time frame: Baseline, Week 48

  15. Main and Extension Study: Percent Change From Baseline in N-Terminal Type III Collagen Propeptide (Pro-C3)

    Baseline was prior to dosing on Day 1 of the main study.

    Time frame: Baseline, Week 48

  16. Main and Extension Study: Percent Change From Baseline in Hepatic Fat Fraction By Magnetic Resonance Imaging - (MRI-PDFF)

    Baseline was prior to dosing on Day 1 of the main study.

    Time frame: Baseline, Week 48

  17. Main and Extension Study: Trough Serum Concentration of Pegozafermin

    Serum trough concentration (ng/mL) of pegozafermin taken from pre-dose samples.

    Time frame: Predose at Week 48

  18. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of IP, whether or not considered related to the IP. TEAEs were defined as AEs that started or worsened on or after the first dose of study IP up to Week 51. An SAE was an AE that met at least 1 of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization for the AE, persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly/birth defect, important medical event or reaction. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Baseline up to Week 51

07

Results

Posted Jan 6, 2026

Participant flow

Main Study (24 Weeks)
Participant flow — Main Study (24 Weeks)
MilestoneMain and Extension Study: Pegozafermin 15 mg QWMain and Extension Study: Pegozafermin 30 mg QWMain and Extension Study: Pegozafermin 44 mg Q2WMain Study: Placebo PooledMain and Extension Study: Placebo (Main) and Placebo (Extension) OnlyMain and Extension Study: Placebo (Main) and Pegozafermin 30 mg QW (Extension)
Started2173577100
Received at least 1 dose of study drug2172576900
Safety analysis set2172576900
Pharmacokinetic (pk) analysis set146651000
Mri-pdff analysis set1461495700
Full analysis set1466516100
Completed2059516300
Not completed1146800
Withdrew: Adverse event162100
Withdrew: Withdrawal by subject033300
Withdrew: Lost to follow-up020200
Withdrew: Physician decision020000
Withdrew: Protocol violation001000
Withdrew: Randomized in error010200
Extension Study (24 Weeks)
Participant flow — Extension Study (24 Weeks)
MilestoneMain and Extension Study: Pegozafermin 15 mg QWMain and Extension Study: Pegozafermin 30 mg QWMain and Extension Study: Pegozafermin 44 mg Q2WMain Study: Placebo PooledMain and Extension Study: Placebo (Main) and Placebo (Extension) OnlyMain and Extension Study: Placebo (Main) and Pegozafermin 30 mg QW (Extension)
Started20565004219
Received at least 1 dose of study drug20564804219
Completed19534203819
Not completed138040
Withdrew: Withdrawal by subject003020
Withdrew: Lost to follow-up011010
Withdrew: Other than specified101010
Withdrew: Adverse event023000

Outcome measures

PrimaryMain Study: Number of Participants With Histological Resolution of Nonalcoholic Steatohepatitis (NASH) Without Worsening of Fibrosis

Nonalcoholic fatty liver disease activity score (NAS) was the sum of the scores of steatosis, inflammation, and ballooning. NAS score ranged from 0 to 8, with higher scores indicating worse disease severity. Resolution of NASH was defined as the total absence of ballooning (score=0) and absent or mild inflammation (score=0 to 1). NASH clinical research system (CRN) fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis). Worsening of fibrosis was defined as progression of fibrosis greater than or equal to (≥) 1 stage in NASH CRN fibrosis score.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Main Study: Number of Participants With Histological Resolution of Nonalcoholic Steatohepatitis (NASH) Without Worsening of Fibrosis
ParticipantsMain Study: Pegozafermin 15 mg QWMain Study: Pegozafermin 30 mg QWMain Study: Pegozafermin 44 mg Q2WMain Study: Placebo Pooled
Main Study: Number of Participants With Histological Resolution of Nonalcoholic Steatohepatitis (NASH) Without Worsening of Fibrosis512111
Statistical analysis
  • Main Study: Pegozafermin 15 mg QW vs Main Study: Placebo Pooled · Cochran-Mantel-Haenszel · p = <0.0001 · Treatment difference: 34.65 · 95% CI 10.04 to 59.26Cochran-Mantel-Haenszel with missing outcome measures handled by multiple imputation method.
  • Main Study: Pegozafermin 30 mg QW vs Main Study: Placebo Pooled · Cochran-Mantel-Haenszel · p = 0.0009 · Treatment difference: 20.89 · 95% CI 9.05 to 32.72Cochran-Mantel-Haenszel with missing outcome measures handled by multiple imputation method.
  • Main Study: Pegozafermin 44 mg Q2W vs Main Study: Placebo Pooled · Cochran-Mantel-Haenszel · p = 0.0005 · Treatment difference: 23.61 · 95% CI 10.04 to 37.18Cochran-Mantel-Haenszel with missing outcome measures handled by multiple imputation method.
PrimaryMain Study: Number of Participants Who Achieved Improvement of Fibrosis ≥1 Stage Without Worsening of NASH

Worsening of NASH was defined as increase in nonalcoholic fatty liver disease activity score (NAS) for ballooning, inflammation, or steatosis. NAS was the sum of the scores of steatosis, inflammation, and ballooning. NAS score ranged from 0 to 8, with higher scores indicating worse disease severity. Fibrosis improvement was defined as ≥1-stage decrease in NASH CRN fibrosis score. NASH CRN fibrosis was staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).

Time frame:
Week 24
Reported as:
Count of participants · Participants
Main Study: Number of Participants Who Achieved Improvement of Fibrosis ≥1 Stage Without Worsening of NASH
ParticipantsMain Study: Pegozafermin 15 mg QWMain Study: Pegozafermin 30 mg QWMain Study: Pegozafermin 44 mg Q2WMain Study: Placebo Pooled
Main Study: Number of Participants Who Achieved Improvement of Fibrosis ≥1 Stage Without Worsening of NASH314114
Statistical analysis
  • Main Study: Pegozafermin 15 mg QW vs Main Study: Placebo Pooled · Cochran-Mantel-Haenszel · p = 0.1039 · Treatment difference: 14.45 · 95% CI -8.71 to 37.62
  • Main Study: Pegozafermin 30 mg QW vs Main Study: Placebo Pooled · Cochran-Mantel-Haenszel · p = 0.0085 · Treatment difference: 18.87 · 95% CI 5.24 to 32.50
  • Main Study: Pegozafermin 44 mg Q2W vs Main Study: Placebo Pooled · Cochran-Mantel-Haenszel · p = 0.0077 · Treatment difference: 20.33 · 95% CI 5.26 to 35.40
SecondaryMain Study: Number of Participants With at Least a 2-Point Improvement in NAS and no Worsening of Fibrosis

NAS was the sum of the scores of steatosis, inflammation, and ballooning. NAS score ranged from 0 to 8, with higher scores indicating worse disease severity. Worsening of fibrosis was defined as progression of fibrosis ≥1 stage in NASH CRN fibrosis score. NASH CRN fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).

Time frame:
Week 24
Reported as:
Count of participants · Participants
Main Study: Number of Participants With at Least a 2-Point Improvement in NAS and no Worsening of Fibrosis
ParticipantsMain Study: Pegozafermin 15 mg QWMain Study: Pegozafermin 30 mg QWMain Study: Pegozafermin 44 mg Q2WMain Study: Placebo Pooled
Main Study: Number of Participants With at Least a 2-Point Improvement in NAS and no Worsening of Fibrosis5342613
SecondaryMain Study: Number of Participants With NASH Resolution and Fibrosis Improvement ≥1 Stage

NAS was the sum of the scores of steatosis, inflammation, and ballooning. NAS score ranged from 0 to 8, with higher scores indicating worse disease severity. Resolution of NASH was defined as the total absence of ballooning (score=0) and absent or mild inflammation (score=0 to 1). Fibrosis improvement was defined as ≥1-stage decrease in NASH CRN fibrosis score. NASH CRN fibrosis was staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).

Time frame:
Week 24
Reported as:
Count of participants · Participants
Main Study: Number of Participants With NASH Resolution and Fibrosis Improvement ≥1 Stage
ParticipantsMain Study: Pegozafermin 15 mg QWMain Study: Pegozafermin 30 mg QWMain Study: Pegozafermin 44 mg Q2WMain Study: Placebo Pooled
Main Study: Number of Participants With NASH Resolution and Fibrosis Improvement ≥1 Stage2780
SecondaryMain Study: Number of Participants With at Least a 2-point Improvement in NAS Score and Are Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF) Responders and Alanine Aminotransferase (ALT) Responders

A responder was defined as achieving ≥2 point improvement in NAS score and are MRI-PDFF responders and ALT responders at Week 24. NAS was the sum of the scores of steatosis, inflammation, and ballooning. NAS score ranged from 0 to 8, with higher scores indicating worse disease severity. MRI-PDFF responder was defined as ≥30% reduction from baseline in liver fat by MRI-PDFF. ALT responder was defined as ≥17 units/liter (U/L) or ≥30% reduction from baseline in ALT.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Main Study: Number of Participants With at Least a 2-point Improvement in NAS Score and Are Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF) Responders and Alanine Aminotransferase (ALT) Responders
ParticipantsMain Study: Pegozafermin 15 mg QWMain Study: Pegozafermin 30 mg QWMain Study: Pegozafermin 44 mg Q2WMain Study: Placebo Pooled
Main Study: Number of Participants With at Least a 2-point Improvement in NAS Score and Are Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF) Responders and Alanine Aminotransferase (ALT) Responders431225
SecondaryMain Study: Percent Change From Baseline in Serum Triglycerides
Time frame:
Baseline, Week 24
Reported as:
Mean · Percent change
Main Study: Percent Change From Baseline in Serum Triglycerides
Percent changeMain Study: Pegozafermin 15 mg QWMain Study: Pegozafermin 30 mg QWMain Study: Pegozafermin 44 mg Q2WMain Study: Placebo Pooled
Main Study: Percent Change From Baseline in Serum Triglycerides-5.79 ± 19.473-14.87 ± 54.765-7.79 ± 29.6121.02 ± 31.425
SecondaryMain Study: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-c)
Time frame:
Baseline, Week 24
Reported as:
Mean · Percent change
Main Study: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-c)
Percent changeMain Study: Pegozafermin 15 mg QWMain Study: Pegozafermin 30 mg QWMain Study: Pegozafermin 44 mg Q2WMain Study: Placebo Pooled
Main Study: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-c)20.28 ± 74.840-0.42 ± 35.290-5.64 ± 31.9440.32 ± 30.811
SecondaryMain Study: Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-c)
Time frame:
Baseline, Week 24
Reported as:
Mean · Percent change
Main Study: Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-c)
Percent changeMain Study: Pegozafermin 15 mg QWMain Study: Pegozafermin 30 mg QWMain Study: Pegozafermin 44 mg Q2WMain Study: Placebo Pooled
Main Study: Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-c)-3.04 ± 18.421-6.94 ± 21.260-6.95 ± 24.120-0.46 ± 24.081
SecondaryMain Study: Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-c)
Time frame:
Baseline, Week 24
Reported as:
Mean · Percent change
Main Study: Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-c)
Percent changeMain Study: Pegozafermin 15 mg QWMain Study: Pegozafermin 30 mg QWMain Study: Pegozafermin 44 mg Q2WMain Study: Placebo Pooled
Main Study: Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-c)4.69 ± 13.44115.82 ± 20.3767.31 ± 18.690-2.01 ± 13.592
SecondaryMain Study: Percent Change From Baseline in Adiponectin
Time frame:
Baseline, Week 24
Reported as:
Mean · Percent change
Main Study: Percent Change From Baseline in Adiponectin
Percent changeMain Study: Pegozafermin 15 mg QWMain Study: Pegozafermin 30 mg QWMain Study: Pegozafermin 44 mg Q2WMain Study: Placebo Pooled
Main Study: Percent Change From Baseline in Adiponectin22.73 ± 44.04531.36 ± 49.21526.60 ± 46.353-6.28 ± 23.770
SecondaryMain Study: Percent Change From Baseline in HbA1c (Glycated Hemoglobin)
Time frame:
Baseline, Week 24
Reported as:
Mean · Percent change
Main Study: Percent Change From Baseline in HbA1c (Glycated Hemoglobin)
Percent changeMain Study: Pegozafermin 15 mg QWMain Study: Pegozafermin 30 mg QWMain Study: Pegozafermin 44 mg Q2WMain Study: Placebo Pooled
Main Study: Percent Change From Baseline in HbA1c (Glycated Hemoglobin)-2.24 ± 13.039-3.74 ± 11.216-2.00 ± 11.742-0.52 ± 9.012
SecondaryMain Study: Percent Change From Baseline in Alanine Transaminase
Time frame:
Baseline, Week 12 and 24
Reported as:
Mean · Percent change
Main Study: Percent Change From Baseline in Alanine Transaminase
Percent changeMain Study: Pegozafermin 15 mg QWMain Study: Pegozafermin 30 mg QWMain Study: Pegozafermin 44 mg Q2WMain Study: Placebo Only Pooled
Change at Week 12-39.68 ± 33.615-42.04 ± 23.044-35.42 ± 28.874-8.62 ± 35.051
Change at Week 24-39.28 ± 31.478-42.73 ± 25.218-31.33 ± 43.053-0.41 ± 48.798
SecondaryMain Study: Percent Change From Baseline in Hepatic Fat Fraction By Magnetic Resonance Imaging - (MRI-PDFF)
Time frame:
Baseline, Week 12 and 24
Reported as:
Mean · Percent Change
Main Study: Percent Change From Baseline in Hepatic Fat Fraction By Magnetic Resonance Imaging - (MRI-PDFF)
Percent ChangeMain Study: Pegozafermin 15 mg QWMain Study: Pegozafermin 30 mg QWMain Study: Pegozafermin 44 mg Q2WMain Study: Placebo Only Pooled
Change at Week 12-45.05 ± 25.857-57.07 ± 19.563-50.63 ± 21.225-0.53 ± 42.062
Change at Week 24-27.92 ± 35.209-51.05 ± 24.065-42.90 ± 40.257-5.80 ± 47.605
SecondaryMain Study: Percent Change From Baseline in N-Terminal Type III Collagen Propeptide (Pro-C3)
Time frame:
Baseline, Week 12 and 24
Reported as:
Mean · Percent Change
Main Study: Percent Change From Baseline in N-Terminal Type III Collagen Propeptide (Pro-C3)
Percent ChangeMain Study: Pegozafermin 15 mg QWMain Study: Pegozafermin 30 mg QWMain Study: Pegozafermin 44 mg Q2WMain Study: Placebo Only Pooled
Change at Week 12-35.34 ± 26.673-9.51 ± 37.151-13.84 ± 25.42010.57 ± 33.392
Change at Week 24-17.10 ± 34.345-17.76 ± 28.250-15.22 ± 27.4299.46 ± 45.403
SecondaryMain Study: Trough Serum Concentration of Pegozafermin

Serum trough concentration (ng/mL) of pegozafermin taken from pre-dose samples.

Time frame:
Predose at Week 12 and 24
Reported as:
Mean · nanograms/milliliter
Main Study: Trough Serum Concentration of Pegozafermin
nanograms/milliliterMain Study: Pegozafermin 15 mg QWMain Study: Pegozafermin 30 mg QWMain Study: Pegozafermin 44 mg Q2W
Week 12197.833 ± 110.097534.289 ± 375.14981.699 ± 77.099
Week 24168.127 ± 158.749691.424 ± 718.49584.033 ± 77.896
SecondaryMain and Extension Study: Percent Change From Baseline in Alanine Transaminase

Baseline was prior to dosing on Day 1 of the main study.

Time frame:
Baseline, Week 48
Reported as:
Mean · Percent change
Main and Extension Study: Percent Change From Baseline in Alanine Transaminase
Percent changeMain and Extension Study: Pegozafermin 15 mg QWMain and Extension Study: Pegozafermin 30 mg QWMain and Extension Study: Pegozafermin 44 mg Q2WMain and Extension Study: Placebo (Main) and Placebo (Extension) OnlyMain and Extension Study: Placebo (Main) and Pegozafermin 30 mg QW (Extension)
Main and Extension Study: Percent Change From Baseline in Alanine Transaminase-28.51 ± 37.164-45.08 ± 25.068-38.05 ± 28.256-5.03 ± 43.918-31.71 ± 46.868
SecondaryMain and Extension Study: Percent Change From Baseline in N-Terminal Type III Collagen Propeptide (Pro-C3)

Baseline was prior to dosing on Day 1 of the main study.

Time frame:
Baseline, Week 48
Reported as:
Mean · Percent Change
Main and Extension Study: Percent Change From Baseline in N-Terminal Type III Collagen Propeptide (Pro-C3)
Percent ChangeMain and Extension Study: Pegozafermin 15 mg QWMain and Extension Study: Pegozafermin 30 mg QWMain and Extension Study: Pegozafermin 44 mg Q2WMain and Extension Study: Placebo (Main) and Placebo (Extension) OnlyMain and Extension Study: Placebo (Main) and Pegozafermin 30 mg QW (Extension)
Main and Extension Study: Percent Change From Baseline in N-Terminal Type III Collagen Propeptide (Pro-C3)-7.89 ± 21.069-16.82 ± 23.675-14.96 ± 21.3421.64 ± 33.082-17.22 ± 23.053
SecondaryMain and Extension Study: Percent Change From Baseline in Hepatic Fat Fraction By Magnetic Resonance Imaging - (MRI-PDFF)

Baseline was prior to dosing on Day 1 of the main study.

Time frame:
Baseline, Week 48
Reported as:
Mean · Percent Change
Main and Extension Study: Percent Change From Baseline in Hepatic Fat Fraction By Magnetic Resonance Imaging - (MRI-PDFF)
Percent ChangeMain and Extension Study: Pegozafermin 15 mg QWMain and Extension Study: Pegozafermin 30 mg QWMain and Extension Study: Pegozafermin 44 mg Q2WMain and Extension Study: Placebo (Main) and Placebo (Extension) OnlyMain and Extension Study: Placebo (Main) and Pegozafermin 30 mg QW (Extension)
Main and Extension Study: Percent Change From Baseline in Hepatic Fat Fraction By Magnetic Resonance Imaging - (MRI-PDFF)-23.93 ± 33.557-48.75 ± 29.717-25.93 ± 50.980-3.15 ± 47.992-59.14 ± 25.807
SecondaryMain and Extension Study: Trough Serum Concentration of Pegozafermin

Serum trough concentration (ng/mL) of pegozafermin taken from pre-dose samples.

Time frame:
Predose at Week 48
Reported as:
Mean · nanograms/milliliter
Main and Extension Study: Trough Serum Concentration of Pegozafermin
nanograms/milliliterMain and Extension Study: Pegozafermin 15 mg QWMain and Extension Study: Pegozafermin 30 mg QWMain and Extension Study: Pegozafermin 44 mg Q2WMain and Extension Study: Placebo (Main) and Pegozafermin 30 mg QW (Extension)
Main and Extension Study: Trough Serum Concentration of Pegozafermin206.54 ± 93.104471.28 ± 397.691111.00 ± 88.644553.45 ± 651.882
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of IP, whether or not considered related to the IP. TEAEs were defined as AEs that started or worsened on or after the first dose of study IP up to Week 51. An SAE was an AE that met at least 1 of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization for the AE, persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly/birth defect, important medical event or reaction. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Baseline up to Week 51
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsMain and Extension Study: Pegozafermin 15 mg QWMain and Extension Study: Pegozafermin 30 mg QWMain and Extension Study: Pegozafermin 44 mg Q2WMain and Extension Study: Placebo (Main) and Placebo (Extension) OnlyMain and Extension Study: Placebo (Main) and Pegozafermin 30 mg QW (Extension)
TEAEs2163464217
SAEs15862

Adverse events

Collected over Baseline up to Week 51. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Main and Extension Study: Pegozafermin 15 mg QW0/21 (0%)1/21 (4.8%)21/21 (100%)
Main and Extension Study: Pegozafermin 30 mg QW0/72 (0%)5/72 (6.9%)62/72 (86.1%)
Main and Extension Study: Pegozafermin 44 mg Q2W0/57 (0%)8/57 (14%)45/57 (78.9%)
Main and Extension Study: Placebo (Main) and Placebo (Extension) Only0/50 (0%)6/50 (12%)41/50 (82%)
Main and Extension Study: Placebo (Main) and Pegozafermin 30 mg QW (Extension)0/19 (0%)2/19 (10.5%)17/19 (89.5%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventMain and Extension Study: Pegozafermin 15 mg QWMain and Extension Study: Pegozafermin 30 mg QWMain and Extension Study: Pegozafermin 44 mg Q2WMain and Extension Study: Placebo (Main) and Placebo (Extension) OnlyMain and Extension Study: Placebo (Main) and Pegozafermin 30 mg QW (Extension)
Tibia fractureInjury, poisoning and procedural complications0/210/720/570/501/19
HypoglycaemiaMetabolism and nutrition disorders0/210/720/570/501/19
Pancreatitis acuteGastrointestinal disorders1/210/720/570/500/19
PneumoniaInfections and infestations0/210/720/571/500/19
Angina pectorisCardiac disorders0/210/720/571/500/19
Diastolic dysfunctionCardiac disorders0/210/720/571/500/19
Myocardial infarctionCardiac disorders0/210/720/571/500/19
DepressionPsychiatric disorders0/210/720/571/500/19
Post-traumatic stress disorderPsychiatric disorders0/210/720/571/500/19
Suicide attemptPsychiatric disorders0/210/720/571/500/19
Most frequent other events
Showing 10 of 65
Most frequent other events
EventMain and Extension Study: Pegozafermin 15 mg QWMain and Extension Study: Pegozafermin 30 mg QWMain and Extension Study: Pegozafermin 44 mg Q2WMain and Extension Study: Placebo (Main) and Placebo (Extension) OnlyMain and Extension Study: Placebo (Main) and Pegozafermin 30 mg QW (Extension)
NauseaGastrointestinal disorders5/2126/7211/575/505/19
DiarrhoeaGastrointestinal disorders5/2118/729/575/502/19
Injection site pruritusGeneral disorders0/216/723/570/504/19
HeadacheNervous system disorders2/216/726/573/504/19
COVID-19Infections and infestations4/2114/728/579/503/19
Procedural painInjury, poisoning and procedural complications4/210/721/572/500/19
HypertensionVascular disorders4/212/722/570/501/19
VomitingGastrointestinal disorders2/2113/722/572/502/19
Injection site erythemaGeneral disorders3/2111/723/573/502/19
Increased appetiteMetabolism and nutrition disorders2/2111/724/572/501/19

Baseline characteristics

Randomized analysis set included all enrolled participants who were assigned a randomization number in the study.

Age, Continuous
Age, Continuous(years)Main and Extension Study: Pegozafermin 15 mg QWMain and Extension Study: Pegozafermin 30 mg QWMain and Extension Study: Pegozafermin 44 mg Q2WMain Study: Placebo PooledTotal
Mean55.0 ± 10.4555.3 ± 11.1555.2 ± 11.2356.3 ± 9.0155.6 ± 10.41
Sex: Female, Male
Sex: Female, Male(Participants)Main and Extension Study: Pegozafermin 15 mg QWMain and Extension Study: Pegozafermin 30 mg QWMain and Extension Study: Pegozafermin 44 mg Q2WMain Study: Placebo PooledTotal
Female9502039118
Male12233732104
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Main and Extension Study: Pegozafermin 15 mg QWMain and Extension Study: Pegozafermin 30 mg QWMain and Extension Study: Pegozafermin 44 mg Q2WMain Study: Placebo PooledTotal
Hispanic or Latino932202485
Not Hispanic or Latino12413747137
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Main and Extension Study: Pegozafermin 15 mg QWMain and Extension Study: Pegozafermin 30 mg QWMain and Extension Study: Pegozafermin 44 mg Q2WMain Study: Placebo PooledTotal
American Indian or Alaska Native00011
Asian11114
Native Hawaiian or Other Pacific Islander00101
Black or African American13004
White18695467208
More than one race00011
Unknown or Not Reported10113
08

Study locations

89 sites
  • 89bio Clinical Study Site
    Birmingham, Alabama 35209, United States
  • 89bio Clinical Study Site
    Birmingham, Alabama 35211, United States
  • 89bio Clinical Study Site
    Dothan, Alabama 36305, United States
  • 89bio Clinical Study Site
    Guntersville, Alabama 35976, United States
  • 89bio Clinical Study Site
    Madison, Alabama 35758, United States
  • 89bio Clinical Study Site
    Chandler, Arizona 85224, United States
  • 89bio Clinical Study Site
    Glendale, Arizona 85036, United States
  • 89bio Clinical Study Site
    Peoria, Arizona 85306, United States
  • 89bio Clinical Study Site
    Tucson, Arizona 85712-4044, United States
  • 89bio Clinical Study Site
    Tucson, Arizona 85712-4046, United States
  • 89bio Clinical Study Site
    Tucson, Arizona 85741, United States
  • 89bio Clinical Study Site
    Little Rock, Arkansas 72205-6414, United States
  • 89bio Clinical Study Site
    Little Rock, Arkansas 72205, United States
  • 89bio Clinical Study Site
    Chula Vista, California 91911, United States
  • 89bio Clinical Study Site
    Huntington Park, California 90255, United States
  • 89bio Clinical Study Site
    Long Beach, California 90808, United States
  • 89bio Clinical Study Site
    Orange, California 92866, United States
  • 89bio Clinical Study Site
    Panorama City, California 91402, United States
  • 89bio Clinical Study Site
    Rialto, California 92377, United States
  • 89bio Clinical Study Site
    Santa Ana, California 92704, United States
  • 89bio Clinical Study Site
    Englewood, Colorado 80113, United States
  • 89bio Clinical Study Site
    Boynton Beach, Florida 33472, United States
  • 89bio Clinical Study Site
    Bradenton, Florida 34208, United States
  • 89bio Clinical Study Site
    Fort Myers, Florida 33912, United States
  • 89bio Clinical Study Site
    Lakeland, Florida 33805, United States
  • 89bio Clinical Study Site
    Maitland, Florida 32127, United States
  • 89bio Clinical Study Site
    Miami, Florida 33014, United States
  • 89bio Clinical Study Site
    Miami, Florida 33147, United States
  • 89bio Clinical Study Site
    Miami, Florida 33157, United States
  • 89bio Clinical Study Site
    Miami Lakes, Florida 33016, United States
  • 89bio Clinical Study Site
    Ocala, Florida 34471, United States
  • 89bio Clinical Study Site
    Palmetto Bay, Florida 33157, United States
  • 89bio Clinical Study Site
    Pinellas Park, Florida 33781, United States
  • 89bio Clinical Study Site
    Port Orange, Florida 32127, United States
  • 89bio Clinical Study Site
    Sarasota, Florida 34240, United States
  • 89bio Clinical Study Site
    Viera, Florida 32940, United States
  • 89bio Clinical Study Site
    Athens, Georgia 30607, United States
  • 89bio Clinical Study Site
    Sandy Springs, Georgia 30328, United States
  • 89bio Clinical Study Site
    New Albany, Indiana 47150, United States
  • 89bio Clinical Study Site
    South Bend, Indiana 46635, United States
  • 89bio Clinical Study Site
    Iowa City, Iowa 52246, United States
  • 89bio Clinical Study Site
    Topeka, Kansas 66606, United States
  • 89bio Clinical Study Site
    Marrero, Louisiana 70072-3151, United States
  • 89bio Clinical Study Site
    Marrero, Louisiana 70072-3155, United States
  • 89bio Clinical Study Site
    Monroe, Louisiana 71201, United States
  • 89bio Clinical Study Site
    Shreveport, Louisiana 71103, United States
  • 89bio Clinical Study Site
    Glen Burnie, Maryland 21061, United States
  • 89bio Clinical Study Site
    Greenbelt, Maryland 20770, United States
  • 89bio Clinical Study Site
    St Louis, Missouri 63033, United States
  • 89bio Clinical Study Site
    Las Vegas, Nevada 89119, United States
  • 89bio Clinical Study Site
    Las Vegas, Nevada 89121, United States
  • 89bio Clinical Study Site
    Florham Park, New Jersey 07932, United States
  • 89bio Clinical Study Site
    New York, New York 10033, United States
  • 89bio Clinical Study Site
    Concord, North Carolina 28027, United States
  • 89bio Clinical Study Site
    Columbus, Ohio 43210, United States
  • 89bio Clinical Study Site
    Dayton, Ohio 45414, United States
  • 89bio Clinical Study Site
    Springboro, Ohio 45066, United States
  • 89bio Clinical Study Site
    Westlake, Ohio 44145, United States
  • 89bio Clinical Study Site
    Greenwood, South Carolina 29646, United States
  • 89bio Clinical Study Site
    Summerville, South Carolina 29485, United States
  • 89bio Clinical Study Site
    Chattanooga, Tennessee 37411, United States
  • 89bio Clinical Study Site
    Chattanooga, Tennessee 37421, United States
  • 89bio Clinical Study Site
    Hermitage, Tennessee 37076, United States
  • 89bio Clinical Study Site
    Austin, Texas 78757-8051, United States
  • 89bio Clinical Study Site
    Austin, Texas 78757-8059, United States
  • 89bio Clinical Study Site
    Beaumont, Texas 77702, United States
  • 89bio Clinical Study Site
    Dallas, Texas 75234, United States
  • 89bio Clinical Study Site
    Dallas, Texas 75246, United States
  • 89bio Clinical Study Site
    Edinburg, Texas 78539, United States
  • 89bio Clinical Study Site
    Fort Worth, Texas 76104, United States
  • 89bio Clinical Study Site
    Garland, Texas 75044, United States
  • 89bio Clinical Study Site
    Houston, Texas 77030, United States
  • 89bio Clinical Study Site
    Houston, Texas 77099, United States
  • 89bio Clinical Study Site
    San Antonio, Texas 78209, United States
  • 89bio Clinical Study Site
    San Antonio, Texas 78215, United States
  • 89bio Clinical Study Site
    San Antonio, Texas 78229-4801, United States
  • 89bio Clinical Study Site
    San Antonio, Texas 78229-5069, United States
  • 89bio Clinical Study Site
    Waco, Texas 76710, United States
  • 89bio Clinical Study Site
    Waco, Texas 76712, United States
  • 89bio Clinical Study Site
    Wichita Falls, Texas 76301, United States
  • 89bio Clinical Study Site
    Ogden, Utah 84405, United States
  • 89bio Clinical Study Site
    Sandy City, Utah 84092, United States
  • 89bio Clinical Study Site
    Manassas, Virginia 20110, United States
  • 89bio Clinical Study Site
    Richmond, Virginia 23235, United States
  • 89bio Clinical Study Site
    Richmond, Virginia 23249, United States
  • 89bio Clinical Study Site
    Roanoke, Virginia 24014, United States
  • 89bio Clinical Study Site
    Seattle, Washington 98105, United States
  • 89bio Clinical Study Site
    Spokane, Washington 99202, United States
  • 89bio Clinical Study Site
    San Juan, 00927, Puerto Rico
09

References and documents

Publications

  • Tseng CL, Balic K, Charlton RW, Margalit M, Mansbach H, Savic RM. Population Pharmacokinetics and Pharmacodynamics of Pegozafermin in Patients with Nonalcoholic Steatohepatitis. Clin Pharmacol Ther. 2023 Dec;114(6):1323-1331. doi: 10.1002/cpt.3046. Epub 2023 Oct 2. PubMed 37696614 ↗
  • Loomba R, Sanyal AJ, Kowdley KV, Bhatt DL, Alkhouri N, Frias JP, Bedossa P, Harrison SA, Lazas D, Barish R, Gottwald MD, Feng S, Agollah GD, Hartsfield CL, Mansbach H, Margalit M, Abdelmalek MF. Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH. N Engl J Med. 2023 Sep 14;389(11):998-1008. doi: 10.1056/NEJMoa2304286. Epub 2023 Jun 24. PubMed 37356033 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Feb 2023, 20 months.

Results were first posted in Jan 2026, 2 years 10 months after primary completion. A results delay was requested in Feb 2024.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 20 months is close to that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2021
First posted
Jun 18, 2021
StartActual
Jun 4, 2021
Primary completionActual
Feb 14, 2023
CompletionActual
Oct 8, 2024
Results delay requested
Feb 9, 2024
Results first posted
Jan 6, 2026
Last update
Jan 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04929483
Lead sponsor
89bio, Inc.
Responsible party
Sponsor
First posted
Jun 18, 2021
Start date
Jun 4, 2021
Primary completion
Feb 14, 2023
Completion
Oct 8, 2024
Results posted
Jan 6, 2026
Last update
Jan 6, 2026

Study contacts

Millie Gottwald, PharmD
study director · 89bio, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegozafermin

Start the discussion